▪ Viral mimicry in cancer therapy (Sep 22, 2025)

▪ Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial (Sep 24, 2025)

▪ RAD51-mediated homologous recombination is a pro-tumour driver pathway (Sep 23, 2025)

▪ Adaptive cancer therapy: can non-genetic factors become its achilles heel? (Sep 21, 2025)

▪ Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: update on recent developments (Sep 24, 2025)

▪ Microorganisms in Cancer Tertiary Lymphoid Structure Formation (Sep 20, 2025)

▪ KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer (Sep 22, 2025)